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Performance (AIP) tool was developed by combining Microsoft
Visual Basic 6.0 with a series of SQL statements that transform
pharmacy databases into a standardized format. Once stan-
dardized, a second series of SQL statements were applied to
allow tracking of prescription activity levels compared to
expected activity levels over sequentially overlapping periods of
time. RESULTS: AIP detects trends in medication adherence rel-
atively early after the initiation of adherence improvement activ-
ities. This represents a signiﬁcant improvement over traditional
methods for studying the impact of patient interventions on med-
ication adherence and provides opportunities for early modiﬁ-
cation of adherence improvement activities that do not achieve
their intended goals. CONCLUSIONS: AIP allows targeting of
speciﬁc patients for adherence interventions based on persis-
tence. Through use of dynamic ﬁlters, AIP can also identify
health care providers and institutions where adherence improve-
ment initiatives are most needed. Additionally, user-deﬁned ther-
apeutic groupings and intent to treat categorization allows AIP
to generate accurate medication adherence information when
patients are initiated on one medication in a therapeutic class but
ultimately maintained on another medication within a deﬁned
therapeutic class. The Adherence Index of Performance provides
a unique means for monitoring the impact of medication adher-
ence improvement initiatives through analysis of pharmacy
claims databases. AIP converts claims databases into a stan-
dardized format upon which a series of pre-deﬁned analytical
processes can be applied. This allows tracking of prescription
activity levels for both new and continuing patients compared to
expected activity levels over sequentially overlapping periods of
time. It has been successfully used by a number of health care
providers to monitor the impact of adherence interventions on
patients’ medication-taking behaviors.
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(TH) COST USING THE MINIMUM BASIC DATA SET (MBDS)
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OBJECTIVES: Estimates of ﬁxed funding budgets can only be
accurate if all pathology related insurance costs are considered.
In this work we analysed the predictive value of LOS and PT
cost on TH insurance cost as surrogates for total budget esti-
mation. These predictors may already be available prior to the
various other cost elements and act as management indicators.
METHODS: Belgian hospitals register admission data in MBDS;
the Health Authorities make annual data freely available via 
the web (https://tct.fgov.be/etct/) on insurance costs (medicines,
medical or surgical procedures, laboratory requests, others)
relating to hospital stays per All Patients Reﬁned Diagnosis
Related Groups (APRDRG) and per stay severity. Data from 
the year 2000 were analyzed in SPSSWIN12.0 using multiple
forward stepwise linear regression. For each variable the median
value was used. Data transformations were used if appropriate.
RESULTS: On APRDRG-level median TH-cost was signiﬁcantly
correlated to HS-cost (r = 0.858, p < 0.0001) and PT-cost (r =
0.708, p < 0.0001). Median TH-cost increased with stay sever-
ity (minor 1728 Euro, extreme 8984 Euro).The linear regression
model considered the inclusion of the factors LOS, PT-cost, mean
patient age and stay severity on TH-cost; the selected model had
an adjusted R2 = 0.767 and included LOS (change in R2 = 0.691),
PT-cost (change in R2 = 0.038) and minor to moderate severity
(all factors with p < 0.001).The model ﬁtted the data of >340
APRDRGs; liver transplantation, major cardio-vascular surgery,
threatened abortion and alcohol abuse may beneﬁt from speciﬁc
modeling. CONCLUSIONS: LOS and pharmaceutical treatment
cost allow explaining >70% of the variance of the total hospi-
tal-cost as measured in real life MBDS-data; these predictors may
be useful as budget management indicators for a majority of
APRDRGs before detailed ﬁnancial data become available.
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ECONOMIC EVALUATION OF NEW TECHNOLOGIES IN THE
HOSPITAL SETTING: THE EXPERIENCE OF THE AZIENDA
OSPEDALIERA DI VERONA, ITALY
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Azienda Ospedaliera di Verona,Verona, Italy, Italy
OBJECTIVE: To evaluate the opportunity of introducing new
technologies in the medical device formulary of the Azienda
Ospedaliera di Verona. As an example, kyphoplasty evaluation
is described. METHODS: In order to control the medical devices
purchasing process, at the Azienda Ospedaliera di Verona (two
hospitals, one teaching and one general, accounting for about
2000 beds) a multidisciplinary Medical Devices Formulary Com-
mittee (MDFC) was established. The tasks of the MDFC are: to
evaluate the introduction of new medical devices in the hospital
formulary; to monitor the appropriate use of medical devices
after their introduction. The committee approves the introduc-
tion into the formulary of new medical devices with innovative
features, based on documented efﬁcacy and a favourable
cost/beneﬁt ratio. For kyphoplasty, efﬁcacy data were collected
from published literature. Cost information was computed
taking into account: the cost of the device, the personnel, the
operating room, length of stay, from the hospital perspective.
RESULTS: At the time of the evaluation, published evidence
describing the efﬁcacy of kyphoplasty consisted mostly of uncon-
trolled retrospective studies. Regarding cost, the overall cost of
the procedure was calculated as follows: device €2250, medical
and nursing staff €486, health materials and operating room
€185, length of stay €2600, for a total of €5521. The DRG reim-
bursement associated with the use of kyphoplasty with no com-
plications is €4200, which does not cover the overall cost of 
the procedure. CONCLUSIONS: Despite poor clinical data and
unfavourable economic analysis, the MDFC approved the use of
kyphoplasty only for 10 selected patients per year, requiring the
physician to report the outcomes of the treated patients, in order
to re-evaluate the use in the future.
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Newly developed, already licensed, high-priced medical devices
for critically ill patients impose additional costs especially on the
hospital sector. In countries with a DRG-based reimbursement
system there are no economic incentives for hospitals to use the
new technologies as long as the additional costs are not com-
pensated. OBJECTIVES: The objective of this paper is to analyse
the structures of the German health care system which are
involved in the implementation of new high-priced medical tech-
nologies the hospital sector in the reimbursement system and 
to determine key factors of a successful implementation.
METHODS: The institutions involved in the determination of
the catalogue of reimbursed items based on the just newly intro-
duced German DRG-system are described and examined. Illus-
trated by examples the launching of newly emerging medical
devices for inpatient treatment is analysed. Investigated parame-
ters were the number and quality of studies published, the
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involvement of health technology assessment institutions, the
adjustment of the reimbursement system in a time frame allow-
ing the survival of the company, and the dissemination of the
technology. RESULTS: Involvement of objective institutions like
the Federal Committee (GemBA) or the Institute for Reimburse-
ment in the hospital sector (INEK) is necessary to prevent imple-
mentation of new technologies without adequate medical
efﬁcacy and economic effectiveness. For positive recommenda-
tions a critical mass of clinical and health economic studies is
prerequisite. But in time adjustment of the reimbursement cata-
logue, e.g. as new DRG or additional payment to existing DRGs,
seem to be crucial for implementation of a new costly technol-
ogy. CONCLUSION: Slow decisions processes can delay if not
prevent the use of useful new therapeutic technologies. Although
according to the German law cost effectiveness should be con-
sidered in reimbursement decisions, so far it did not play a rel-
evant role in reimbursement decisions in the hospital sector.
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PRESCRIBING PATTERNS AND ASSOCIATED COSTS OF
PSYCHOTROPIC DRUGS IN A MAJOR HEALTH CARE SYSTEM
IN SAUDI ARABIA
Alsultan MS,Al-Sabhan JF
King Saud University College of Pharmacy, Riyadh, Riyadh, Saudi
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OBJECTIVES: Recognizing the prescribing pattern and associ-
ated costs of psychotropic medications and the factors associated
with such prescribing is crucial and may play an important role
in improving the health care services provided to patients on such
medications. The objective of this study was to assess current
trends and factors inﬂuencing the prescribing of psychotropic
medications. The study also estimated the direct cost associated
with these medications. METHODS: This is a retrospective
study of (N = 71,136) prescription events of psychotropic med-
ications identiﬁed from outpatient pharmacy records of a major
health care system in Riyadh, Saudi Arabia for years 2002, 2003,
and 2004. Patient characteristics, psychotropic medications use
and the associated costs over the three years period were deter-
mined. Logistic regression was used to evaluate the inﬂuence of
physician specialty and other relevant factors on prescribing of
different psychotropic medications. RESULTS: Over the three
years period the use of high cost agents have sharply increased
to account for around 8% of the total outpatient spending on
pharmaceuticals in 2004. Prescriptions by General Practitioners
(GPs) accounted for 35% of the total psychotropic medications
prescribed. However, patients on these medications were more
likely to receive a high cost drug from a psychiatrist than from
any other specialty. CONCLUSIONS: The results of the study
indicate that psychotropic medications are mainly prescribed by
GPs and that the likelihood of being prescribed a psychotropic
medication, which may be of high cost, is greater when patients
see a psychiatrist. In Saudi Arabia, health care systems should
closely monitor prescribing patterns for psychotropic medica-
tions to avoid unnecessary cost and consequently, the potential
for inappropriate use of such agents.
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HEALTH DISPARITIES FOR AFRICAN AMERICAN PATIENTS IN
SOUTH CAROLINA DURING 1998–2002
Chumney EC, Simpson K, Mauldin P
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OBJECTIVE: To estimate the ﬁnancial effect of racial disparities
as reﬂected in differences in hospital admission rates each of the
25 Major Diagnostic Categories (MDCs) in the state of South
Carolina. METHODS: Estimates were calculated for total sub-
mitted charges within each MDC that were attributed to higher
admission rates for African Americans than for Caucasians in
South Carolina, based on age-adjusted annual admission rates.
Each of the 25 MDCs was evaluated to reveal which component
Diagnostic Related Groups (DRGs) were the largest admission
“drivers” or contributors to the observed differences in ad-
mission rates. South Carolina hospital discharge data for
1998–2002 was used for the analysis. The database includes all-
payer billing data for inpatient hospital admissions as received
on the UB-92 billing ﬁle for the covered episode. Charges were
inﬂation-adjusted to 2002 constant dollars. RESULTS: Between
1998 and 2002, there were an estimated $1.6 billion in total
charges for hospital admissions in South Carolina that were
attributed to higher age-adjusted admission rates for African-
American patients. In addition, African Americans had consis-
tently higher hospital admission rates for disease categories that
are often associated with a failure to obtain ambulatory and 
preventive care. CONCLUSION: Our analysis reveals that age-
adjusted hospital admission rates for African Americans in South
Carolina are higher than for Caucasians, and that the gap
appears to be widening over time. Given the magnitude of the
ﬁnancial implication, interventions with even a small impact on
the conditions underlying the racial disparities in hospital admis-
sions are likely to be cost-effective.
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OBJECTIVE: Health districts have been established as part of
the decentralization of responsibility within the Italian National
Health Service. A major challenge is to assure that appropriate
ﬁnancing is provided to meet the needs of the population. Risk
adjustment models are being developed that can be used for dis-
tricts’ resource allocation, planning and evaluation activities.
METHODS: Pharmaceutical, hospital, and demographic data
from 2000 and 2001 have been assembled for the entire popu-
lation of Emilia Romagna, a large northern Italian region (4
million). Pharmaceutical and hospital tariffs were a proxy for
costs. Morbidity indicators based upon pharmacy and hospital
data were developed for risk adjustment. Prospective risk adjust-
ment models were ﬁt. We tested several models of increasing
complexity, taking advantage of the predictive power of phar-
macy- and hospital-based diagnostic groups. Our ﬁnal adjuster
was based upon a combination of the pharmacy and hospital
groupings. We considered fairness across administrative units, as
equity was a key policy goal. RESULTS: The pharmacy cost
model predicts 25.8% of the variation in pharmacy costs. Our
hospital cost model predicts 10.1% of variation in prospective
hospital costs. Predictive accuracy for pharmacy cost models
were improved by information from the hospital data; and were
more stable for those who used health services in year 1, and
better for those who used hospital and pharmacy services com-
pared to those who did not have any service use. For the phar-
macy model predictive accuracy by district ranged from 0.91 to
1.10; for the hospital cost model, predictive accuracy by district
ranged from 0.93 to 1.13. CONCLUSIONS: We demonstrate
that risk adjustment models using pharmacy data to identify
individual morbidity are good predictors of future year costs.
Regional and district health managers can use these models for
